Table 1 Main characteristics of studies included in meta-analysis
Author(year) | Study region | Study design | Sample size | Study period | Cancer type | Sampling time | Cutoff values | Outcomes, HR estimation | Analysis method | Treatment strategy | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Fucà G (2020) | Italy | retrospective | 438 | 2008–2018 | Colorectal cancer | Before treatment | 380 | OS, 1.55(1.02–2.37) PFS, 1.53 (1.09–2.15) | U/M | Chemotherapy; Target therapy | 8 |
Baba Y (2021) (Validation ) | Japan | retrospective | 433 | 2005–2020 | Esophageal cancer | Within 1 week before treatment | 164.6 | OS, 1.37 (1.02–1.85) | U/M | Surgery | 8 |
Baba Y (2021) (Derivation ) | OS, 1.63(1.22–2.19) | U | Surgery | 7 | |||||||
Corti F (2021) | Italy | retrospective | 163 | 2014–2020 | Colorectal cancer | Within 1 week before treatment | 492 | OS, 3.21 (1.65–6.23) PFS, 2.25 (1.30–3.89) | U/M | Immunotherapy | 8 |
Karadağ I (2022) | Turkey | retrospective | 120 | 2013–2021 | Hepatocellular cancer | Before treatment | 286.15 | OS, 1.813 (1.119–2.938) | M | Mixed therapy | 7 |
Pérez-Martelo M (2022) | Spain | retrospective | 130 | 2015–2018 | Colorectal cancer | Within 1 month before treatment | 380 | OS, 1.823(1.146–2.898) PFS, 1.561(1.054–2.311) | U/M | Chemotherapy | 8 |
Sato S (2022) | Japan | retrospective | 758 | 2000–2019 | Colorectal cancer | Before treatment | 376 | OS, 2.485(1.552–3.981) RFS, 1.697(1.097–2.624) | U/M | Surgery | 8 |
Topkan E (2022) | Turkey | retrospective | 178 | 2007–2020 | Pancreatic adenocarcinoma | Before treatment | 464 | OS, 2.86(2.58–3.14) PFS, 3.04(2.87–3.21) | M | Chemoradiotherapy | 7 |
Wang SB (2022) | China | retrospective | 89 | 2010–2018 | Gastric cancer | Before treatment | 218.7 | DFS, 1.611 (0.795–3.264) | U | Surgery | 6 |
Efil SC (2023) | Turkey | retrospective | 304 | 2008–2016 | Colorectal cancer | Within 2 weeks before treatment | 491 | OS, 2.44(1.55–3.82) DFS, 2.28(1.50–3.45) | U | Surgery | 7 |
Feng J (2023) | China | retrospective | 294 | 2013–2014 | Esophageal Cancer | Within 1 week before treatment | 308.2 | CSS, 1.983 (1.475–2.664) | U/M | Surgery | 7 |
Feng J (2023) | China | retrospective | 218 | 2019–2021 | Esophageal Cancer | Before treatment | 373.6 | OS, 2.364 (1.183–4.724) DFS, 1.729 (1.026–2.913) | U/M | Surgery | 8 |
Qi WX (2023) | China | retrospective | 51 | 2019–2022 | Esophageal Cancer | Before treatment | 232.8 | PFS, 2.08(0.68–6.25) | U | Chemoradiotherapy; Target therapy | 6 |
Sato R (2023) | Japan | retrospective | 86 | 2013–2020 | Colorectal cancer | Before treatment | 209 | RFS, 3.99(1.69–9.45) CSS, 3.41(1.12–10.38) | M | Surgery | 7 |
Wang HK (2023) | China | retrospective | 356 | 2013–2019 | Esophageal Cancer | Within 1 week before treatment | 178.055 | OS, 4.099(1.127–14.902) | U/M | Surgery | 8 |
Yeh CC (2023) | China | retrospective | 853 | 2005–2017 | Oral cavity carcinoma | Before treatment | 268 | OS, 1.281(1.027–1.596) DFS, 1.165(0.943–1.438) | U/M | Surgery | 8 |
Fu M (2024) | China | retrospective | 84 | 2018–2023 | Gastric cancer | Within 1 week before treatment | 499.08 | OS, 0.56(0.05–6.55) | U | Immunotherapy | 7 |
Fu M (2024) | China | retrospective | 107 | 2019–2023 | Esophageal Cancer | Within 1 week before treatment | 415.885 | OS, 2.35(1.31–4.20) | U | Immunotherapy | 7 |
Liu Q (2024) | China | retrospective | 172 | 2018–2019 | Colorectal cancer | Before treatment | 265.75 | OS, 2.476(1.410–4.348) | U/M | Surgery | 8 |
Seo YJ (2024) | Korea | retrospective | 203 | 2016–2020 | Colorectal cancer | 2 days before the surgery | 155.90 | OS, 8.363(1.028–68.016) DFS, 2.215 (0.596–8.235) | M | Surgery | 7 |